Navigation Links
Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
Date:10/7/2008

nt that has the potential to extend the lives of people with advanced prostate cancer. Administered subcutaneously, it induces a specific, targeted immune response that attacks metastatic cells in the prostate. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with numerous side effects. In contrast, PROSTVAC(TM) has the potential to extend survival with improved quality of life.

In clinical trials to date PROSTVAC(TM) has been investigated in 464 patients over 10 years. The Phase III programme is currently being planned.

About prostate cancer

Prostate cancer had an incidence of more than 500,000 cases worldwide in 2007. It has thus become the most frequent cancer in men and has become more frequent than lung cancer and colon cancer. With estimated more than 140,000 related deaths annually, prostate cancer is the third leading cause of cancer related deaths in men. The age adjusted cancer death rates for prostate cancer have doubled since 1930; among other leading malignant diseases only lung cancer has shown a worse development in this century. These tendencies developed even though the five year survival rates for localized prostate cancer have been continuously improved. However, the treatment for metastatic prostate cancer has not been improved in recent years. Prostate cancer is resistant to conventional chemotherapy. The only mechanism that has been used so far in disseminated disease with some effect is hormone treatment. Hormone therapy slows the tumor growth by stopping or blocking testosterone from entering the cancer cells. Prostate cancer cells are typically dependent on testosterone or other androgens as growth factors. Thus, although initially effective, hormone therapy becomes ineffective after a period of time. Chemotherapy for disseminated disease at this stage is very limited with only one chemotherapeutic agent approved for the treatment of metastatic prostate
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bavarian Nordic Enters Clinical Trials with HIV Multiantigen Vaccine
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- Inc. magazine today ... third straight year, No. 349 in Health on ... of the nation,s fastest-growing private companies. The list ... important segment of the economy—America,s independent entrepreneurs. Companies ... LinkedIn, Zillow, and many other well-known names gained ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... 11, 2007 - New data,supporting the clinical development ... oral protease inhibitors for the,treatment of hepatitis C ... Annual Meeting of the European Association for the,Study ... In total, nine,abstracts related to telaprevir have been ...
... 11, 2007 /PRNewswire-FirstCall/ -- Vical,Incorporated today announced ... company's Vaxfectin(TM) adjuvant generated up,to 60-fold higher ... same dose in a recently completed study ... vaccine with,Vaxfectin(TM) also allowed a nearly 10-fold ...
Cached Medicine Technology:Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 2Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 3Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 4Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 5
(Date:8/23/2014)... Cardiomyopathy (heart muscle disease) is ... myocardium (the heart muscle) for any reason, usually ... (breathlessness) and peripheral edema (swelling of the legs). ... dangerous forms of irregular heart beat and sudden ... is dilated cardiomyopathy. , Clinical trial report, “Cardiomyopathy ...
(Date:8/23/2014)... 23, 2014 The report “Polycarbonate ... & Forecasts to 2018” defines and segments the ... of the global revenue and consumption. It also ... polycarbonate resin market with analysis of trends, opportunities, ... and consumption and revenues are forecasted on the ...
(Date:8/23/2014)... 2014 According to the new ... Application and Geography - Regional Trends & Forecast ... Market with an analysis and forecast of value ... of electronic adhesives by applications and geography are ... market data tables and 26 figures spread through ...
(Date:8/23/2014)... August 23, 2014 A team of New ... last longer when preceded by surgery and delivered by an ... the new study. Click here to read it now ... the cases of mesothelioma patients who underwent hemithoracic ... radiotherapy dose to the shape of a tumor. Patients ...
(Date:8/23/2014)... August 23, 2014 On Monday, August ... a data breach suffered by Community Health Systems, ... compromise of 4.5 million records containing Personally Identifiable Information ... According to Mandiant, who was engaged to investigate the ... an advanced group of cyber attackers based in China, ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 3Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4
... Reports’ has just enabled some valuable advice about chicken, which ... From virus to bacteria//, chicken seems to be hounded incessantly ... of 525 chickens, it found that nearly 83% of the ... or both. The bacteria are known to trigger diarrhea, cramping, ...
... study conducted by Asher Chanan-Khan, MD, Department of Medicine, ... for relapsed chronic lymphocytic leukemia (CLL) or diseases that ... response to the therapy. The results of this study ... Journal of Clinical Oncology. ,"Chronic lymphocytic ...
... a global initiative to develop a vaccine against malaria,// the ... ,The objective for the ‘Malaria Vaccine Technology Roadmap’ is ... fight Malaria by the year 2015. ,Malaria ... and rightly it is one of the oldest diseases in ...
... The popular hair-growth drug finasteride, taken by millions of ... antigen (PSA) test,// the standard screening test for prostate ... involving 308 men ranging in age from 40 to ... medical journal The Lancet and is scheduled to be ...
... was the focus of attention following an E. coli outbreak. ... with abdominal cramps, //fever and diarrhea. They were diagnosed with ... restaurants, operated by Yum Brands Inc in New Jersey have ... of the sick people reported that they had eaten from ...
... under Section 5 of the Insecticides Act, 1968 registers ... safety.// Toxicity and residues data generated under supervised trials ... (MRLs) by the Ministry of Health & Family Welfare ... Rules framed thereunder. The inspection of fruits and vegetables ...
Cached Medicine News:Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
An In Vitro Nucleic Acid Hybridization Assay with Signal Amplification using Microplate Chemiluminescence for the Qualitative Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45,...
Rapid test for the presumptive identification of Candida albicans from culture media....
... is a system built ... and an imaging device ... zone size around an ... built-in expertise for detection ...
The best value and features offered in a complete EMR and Practice Management Solution...
Medicine Products: